Research programme: cancer and autoimmune disorders therapy - CGI Pharmaceuticals/Genentech
Latest Information Update: 10 Mar 2008
At a glance
- Originator CGI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 27 Oct 2006 Preclinical trials in Autoimmune disorders in USA (unspecified route)
- 27 Oct 2006 Preclinical trials in Cancer in USA (unspecified route)